Febuxosaph-40 (Febuxostat 40mg) is a potent, non-purine selective inhibitor of xanthine oxidase, specifically developed to manage high levels of uric acid in the blood (hyperuricemia) in patients with chronic gout. Unlike traditional treatments, Febuxostat works by effectively blocking the enzyme responsible for the production of uric acid, helping to prevent the formation of painful urate crystals in the joints.
This 40mg strength is often used as an initial or maintenance dose to achieve and maintain target serum uric acid levels, reducing the frequency of gout flares and long-term joint damage.
Key Indications:
-
Chronic Hyperuricemia: Long-term management of high uric acid levels in adults with gout.
-
Gout Flare Prevention: Reduces the occurrence of painful gout attacks by maintaining low uric acid levels over time.
-
Alternative to Allopurinol: Suitable for patients who may not have achieved results with other gout medications or who require a different therapeutic approach.
Why Choose Febuxosaph-40?
-
Highly Selective: Targets the xanthine oxidase enzyme with high precision to lower uric acid production.
-
Consistent Control: Designed for daily use to keep uric acid levels stable and within a healthy range.
-
Patient-Friendly: Film-coated tablets are easy to swallow and can be taken with or without food.





